BRIEF published on 05/13/2025 at 22:05, 1 year 4 months ago GenSight Biologics Shareholders Approve Majority of Board's Resolutions Shareholder Meeting Board Resolutions GenSight Biologics LUMEVOQ® Phase III RECOVER
PRESS RELEASE published on 05/13/2025 at 22:00, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics announces approval of all resolutions at Combined General Meeting on May 13, 2025. Company highlights achievements of 2024 and strategic priorities for 2025 Strategic Priorities Approval Combined General Meeting GenSight Biologics Achievements
BRIEF published on 04/23/2025 at 20:35, 1 year 4 months ago GenSight Biologics Announces Annual General Meeting Details Annual General Meeting Shareholders Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 04/23/2025 at 20:30, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 13, 2025 at 2:00 pm CEST in Paris, France. Procedures for obtaining preparatory documents outlined Annual General Meeting Preparatory Documents GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 04/08/2025 at 07:51, 1 year 5 months ago GenSight Biologics Files its 2024 Universal Registration Document AMF Gene Therapy Registration Document GenSight Biologics Retina
BRIEF published on 04/08/2025 at 07:48, 1 year 5 months ago GenSight Biologics Files 2024 Universal Registration Document Universal Registration Document GenSight Biologics Gene Therapies Retinal Diseases Financial Report 2024
PRESS RELEASE published on 04/08/2025 at 07:43, 1 year 5 months ago INSIDE INFORMATION / OTHER NEWS RELEASES GenSight Biologics announces the filing of its 2024 Universal Registration Document with the French market authority, including financial reports and corporate governance details GenSight Biologics Gene Therapies Retinal Neurodegenerative Diseases 2024 Universal Registration Document Central Nervous System Disorders
BRIEF published on 04/07/2025 at 20:19, 1 year 5 months ago GenSight Biologics Financial and Business Update Fundraising Clinical Trials Gene Therapy Financial Update GenSight Biologics
PRESS RELEASE published on 04/07/2025 at 20:14, 1 year 5 months ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and business update as of March 31, 2025. Discussions with French agency progressing. Fundraising planned for Phase III trial and marketing advancement Business Update Cash Position Fundraising Activities GenSight Biologics RECOVER Phase III Trial
BRIEF published on 03/17/2025 at 07:35, 1 year 6 months ago GenSight Biologics Presents LUMEVOQ® at NANOS 2025 Gene Therapy GenSight Biologics LUMEVOQ® NOHL NANOS Congress
Published on 09/17/2026 at 15:55, 50 minutes ago Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 15:25, 1 hour 20 minutes ago AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 1 hour 45 minutes ago Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 1 hour 45 minutes ago ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 1 hour 55 minutes ago Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner
Published on 09/17/2026 at 15:30, 1 hour 14 minutes ago Huawei Introduces OceanStor M900 Context Memory Storage to Accelerate AI Inference in Hyperscale Data Centers
Published on 09/17/2026 at 15:08, 1 hour 36 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/17/2026 at 15:07, 1 hour 38 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 09/17/2026 at 15:06, 1 hour 38 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 09/16/2026 at 17:45, 23 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 9 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 22 hours ago Report on the Combined General Meeting of the 10th of September 2026
